This inventor holds 3 USPTO granted patents, plus 2 CIPO patents. Top assignees: United Therapeutics Corporation, King Pharmaceuticals Research and Development, Inc.. Active years: 2008-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 133 
1 out of 23 Years Active: 2008-2019
Title: Michael Scannell: Innovator in Pharmaceutical Formulations
Introduction
Michael Scannell is a notable inventor based in Holly Springs, NC (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid forms of treprostinil. With a total of 3 patents to his name, Scannell's work has had a meaningful impact on medical formulations.
Latest Patents
Among his latest patents, Scannell has developed individual polymorphic forms of treprostinil and pharmaceutical formulations that comprise these forms. His innovative methods of making and using these formulations are designed to enhance the efficacy of treprostinil in medical applications.
Career Highlights
Throughout his career, Scannell has worked with prominent companies in the pharmaceutical industry. He has been associated with United Therapeutics Corporation and King Pharmaceuticals Research and Development, Inc., where he has contributed to various research and development projects.
Collaborations
Some of his notable coworkers include Kenneth R. Phares and Ken Phares, who have collaborated with him on various projects in the pharmaceutical sector.
Conclusion
Michael Scannell's contributions to the field of pharmaceuticals, particularly through his patents on treprostinil, highlight his role as an innovator in the industry. His work continues to influence the development of effective medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile